Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/4/2025 | $28.00 | Outperform | Robert W. Baird |
| 11/18/2024 | $35.00 | Overweight | Stephens |
| 3/14/2024 | $27.00 | Buy | Citigroup |
| 3/7/2024 | $23.00 | Buy | BofA Securities |
| 12/21/2023 | $30.00 | Outperform | Oppenheimer |
| 8/24/2022 | $10.00 → $15.50 | Buy → Neutral | ROTH Capital |
| 2/8/2022 | $9.00 → $12.00 | Buy | HC Wainwright & Co. |
Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00
Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00
Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00
Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data) Product Revenue, net$149,343$141,400 5.6%FIRDAPSE Product Revenue, net$98,859$83,731 18.1%AGAMREE Product Revenu
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac
As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement ("Agreement") with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private
PREM14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
DEFA14A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the
Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data) Product Revenue, net$149,343$141,400 5.6%FIRDAPSE Product Revenue, net$98,859$83,731 18.1%AGAMREE Product Revenu
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac
CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 12, 2026Time:8:30 AM ETUS/Canada Dial-in
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)